Baird analyst Luke Herrmann raised the firm’s price target on Alkermes (ALKS) to $48 from $45 and keeps an Outperform rating on the shares. The firm updated its model following positive IH Phase 3 data setting up sNDA by the end of 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes announces ‘positive’ topline results from REVITALYZ Phase 3 study
- Alkermes Reports Positive Phase 3 Results for LUMRYZ
- Alkermes Advances Brilliance NT2 Phase 3 Trial, Raising Interest in Narcolepsy Market
- Alkermes price target raised to $48 from $42 at UBS
- Alkermes price target raised to $50 from $45 at Needham